Mirum Pharmaceuticals Inc. (MIRM) has kicked off the year with commercial growth and successful pipeline milestones, propelling its shares to an all-time high of $53.
The company has three approved ultra-rare medicines and 4 clinical programs. Its marketed drugs include Livmarli oral solution and tablets, Cholbam capsules, and Ctexli tablets.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com